Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study.
Saved in:
| Title: | Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study. |
|---|---|
| Authors: | Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Jhaveri K; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States., Helsten T; Moores Cancer Center, University of California San Diego, San Diego, CA, United States., Puhalla SL; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, United States., Conlin A; Providence Cancer Center, Portland, OR, United States., Dees EC; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States., Beeram M; South Texas Accelerated Research Therapeutics, San Antonio, TX, United States., Chapman SC; Eli Lilly and Company, Indianapolis, IN, United States., Lithio A; Eli Lilly and Company, Indianapolis, IN, United States., Litchfield LM; Eli Lilly and Company, Indianapolis, IN, United States., Goetz MP; Department of Oncology, Mayo Clinic, Rochester, MN, United States. |
| Source: | Frontiers in oncology [Front Oncol] 2025 Mar 12; Vol. 15, pp. 1555921. Date of Electronic Publication: 2025 Mar 12 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 40144206 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Tolaney+SM%22">Tolaney SM</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.<br /><searchLink fieldCode="AU" term="%22Jhaveri+K%22">Jhaveri K</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.<br /><searchLink fieldCode="AU" term="%22Helsten+T%22">Helsten T</searchLink>; Moores Cancer Center, University of California San Diego, San Diego, CA, United States.<br /><searchLink fieldCode="AU" term="%22Puhalla+SL%22">Puhalla SL</searchLink>; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, United States.<br /><searchLink fieldCode="AU" term="%22Conlin+A%22">Conlin A</searchLink>; Providence Cancer Center, Portland, OR, United States.<br /><searchLink fieldCode="AU" term="%22Dees+EC%22">Dees EC</searchLink>; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.<br /><searchLink fieldCode="AU" term="%22Beeram+M%22">Beeram M</searchLink>; South Texas Accelerated Research Therapeutics, San Antonio, TX, United States.<br /><searchLink fieldCode="AU" term="%22Chapman+SC%22">Chapman SC</searchLink>; Eli Lilly and Company, Indianapolis, IN, United States.<br /><searchLink fieldCode="AU" term="%22Lithio+A%22">Lithio A</searchLink>; Eli Lilly and Company, Indianapolis, IN, United States.<br /><searchLink fieldCode="AU" term="%22Litchfield+LM%22">Litchfield LM</searchLink>; Eli Lilly and Company, Indianapolis, IN, United States.<br /><searchLink fieldCode="AU" term="%22Goetz+MP%22">Goetz MP</searchLink>; Department of Oncology, Mayo Clinic, Rochester, MN, United States. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2025 Mar 12; Vol. 15, pp. 1555921. <i>Date of Electronic Publication: </i>2025 Mar 12 (<i>Print Publication: </i>2025). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40144206 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.3389/fonc.2025.1555921 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1555921 Titles: – TitleFull: Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Tolaney SM – PersonEntity: Name: NameFull: Jhaveri K – PersonEntity: Name: NameFull: Helsten T – PersonEntity: Name: NameFull: Puhalla SL – PersonEntity: Name: NameFull: Conlin A – PersonEntity: Name: NameFull: Dees EC – PersonEntity: Name: NameFull: Beeram M – PersonEntity: Name: NameFull: Chapman SC – PersonEntity: Name: NameFull: Lithio A – PersonEntity: Name: NameFull: Litchfield LM – PersonEntity: Name: NameFull: Goetz MP IsPartOfRelationships: – BibEntity: Dates: – D: 12 M: 03 Text: 2025 Mar 12 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 2234-943X Numbering: – Type: volume Value: 15 Titles: – TitleFull: Frontiers in oncology Type: main |
| ResultId | 1 |